Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

2期 进行中（已停止招募） NCT02134925

摘要

This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.

Change in Anti-MUC1 Immunoglobulin G (IgG) Levels as Determined by Enzyme-linked Immunosorbent Assay (ELISA)

Week 0 to week 12 · IgG ratio

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• CryoBalloon Ablation for Treatment of Duodenal Adenomas — Johns Hopkins University
• Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refract — Jennerex Biotherapeutics
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III — National Cancer Institute (NCI)
• Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal — National Cancer Institute (NCI)
• Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating — National Cancer Institute (NCI)
• Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)

全部试验